Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 23 · below the Ichimoku cloud · RSI 51 · MACD above its signal · 5% above its 52-week low
None of the 29 investors followed here reported a position in 0874.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 0874.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for 0874.HK.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.8 | 1.1 | -12.7 | -0.2 | -7.4 | -8.1 | 12.2 | -12.9 | -4.2 | 0.8 | −24.5% | ||
| 2025 | -3.4 | 1.3 | -4.4 | -0.2 | 2.8 | -0.2 | 3.9 | 0.1 | 0.6 | 3.0 | 0.4 | -5.6 | −2.3% |
| 2024 | -12.5 | 7.1 | -5.7 | 8.6 | 6.5 | -7.2 | -3.6 | -2.3 | 6.0 | -11.3 | -1.0 | 0.4 | −16.4% |
| 2023 | -0.4 | 0.9 | 4.8 | 6.4 | 1.9 | -9.9 | -1.3 | -5.6 | 2.3 | -7.8 | 3.6 | 0.9 | −5.4% |
| 2022 | -11.4 | 4.9 | -0.5 | -1.7 | 7.4 | 5.0 | -9.8 | -8.8 | -10.4 | 3.2 | 19.1 | 10.3 | +2.4% |
| 2021 | 2.6 | 1.6 | -4.9 | 11.1 | 12.4 | 4.2 | -14.5 | -5.4 | -0.6 | -0.2 | -3.6 | 18.2 | +18.0% |
| 2020 | -5.3 | -5.6 | -12.2 | -1.9 | -8.1 | 3.8 | 20.4 | -13.8 | -4.7 | -5.1 | 8.8 | -4.8 | −28.5% |
| 2019 | 7.5 | 1.0 | 13.6 | 17.5 | -19.4 | 7.6 | -7.8 | -9.7 | -11.9 | -3.9 | -5.0 | 12.7 | −5.2% |
| 2018 | -0.9 | -7.0 | 13.9 | 25.2 | 35.3 | -15.6 | -3.5 | -13.5 | -3.5 | 2.3 | 10.7 | -11.2 | +21.7% |
| 2017 | -4.9 | 7.8 | 11.4 | -2.8 | -5.2 | 1.7 | -4.0 | -4.0 | 3.1 | 34.3 | -18.1 | 2.7 | +15.0% |
| 2016 | -21.9 | -5.5 | 8.1 | -5.9 | 6.9 | 3.9 | 5.0 | 2.7 | -3.5 | -3.7 | 1.7 | 7.4 | −8.7% |
| 2015 | 17.7 | -5.8 | 2.7 | 11.2 | 8.8 | -11.5 | -25.7 | -11.5 | 5.9 | 10.1 | -10.7 | 12.2 | −6.4% |
| 2014 | -7.2 | -0.6 | 5.0 | -12.2 | 3.7 | -5.2 | 9.3 | 8.9 | -1.5 | -0.4 | -11.3 | -0.2 | −13.6% |
| 2013 | 30.7 | 4.8 | 38.0 | -2.3 | 21.9 | -8.9 | 5.3 | -2.0 | 16.7 | -17.2 | 4.6 | -7.7 | +97.3% |
| 2012 | 0.0 | 0.0 | 15.7 | 8.0 | 67.5 | 8.3 | -1.6 | 6.6 | 1.2 | 3.0 | -13.4 | 5.5 | +126.7% |
| 2011 | -10.4 | -3.6 | -14.4 | -7.7 | -6.3 | -2.4 | 0.5 | -17.1 | -27.7 | 14.7 | 9.6 | 0.0 | −52.8% |
| 2010 | 1.0 | 14.0 | 15.9 | 16.3 | -17.7 | -12.0 | 2.7 | 2.7 | 20.6 | -1.3 | 37.2 | 13.6 | +119.8% |
| 2009 | -9.2 | 3.8 | 6.1 | 17.6 | 3.2 | 31.1 | -4.3 | -7.0 | -1.6 | 3.0 | 37.8 | 12.9 | +123.3% |
| 2008 | -34.6 | 36.4 | -17.3 | 17.7 | 8.5 | -24.3 | -9.4 | -18.8 | -29.0 | -34.3 | 6.6 | 35.1 | −64.7% |
| 2007 | 45.5 | 1.6 | -11.4 | -2.8 | 42.0 | -2.5 | -15.0 | 22.5 | 11.5 | -5.6 | -17.4 | 5.8 | +68.9% |
Buy / hold / sell counts
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices. The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup. In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services. Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
No recent headlines.